MedTrace Logo

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

NCT04247074 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 413

Last updated 2023-09-06

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.

Conditions

  • Glabellar Frown Lines (GL)
  • Lateral Canthal Lines (LCL)

Interventions

BIOLOGICAL

botulinum toxin neuromodulator

QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL

BIOLOGICAL

Placebo

Placebo will be injected into either the LCL, GL, or both the LCL and GL

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-10
Primary Completion
2020-10-02
Completion
2021-02-26
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04247074 on ClinicalTrials.gov